ライフサイエンスコーパス: soluble receptor

1 ous sVEGFR-1, indicating a saturation of the soluble receptor.

2 ng that this auxin response is mediated by a soluble receptor.

3 ng virions at pH 8 and 37 degrees C, without soluble receptor.

4 polyethylene glycol-linked dimer of the TNF soluble receptor.

5 is effect, IL-6 requires the presence of its soluble receptor.

6 2) that appears to be a naturally expressed soluble receptor.

7 hed shedding of the potentially antagonistic soluble receptor.

8 a recombinantly produced chimeric TNF alpha soluble receptor.

9 eptin from circulation due to binding to its soluble receptor.

10 perties similar to the membrane-embedded and soluble receptor.

11 inished shedding of potentially antagonistic soluble receptor.

12 ding the tumor necrosis factor (TNF) and its soluble receptor.

13 tic release of the extracellular domain as a soluble receptor.

14 ite of antigen deposition or is complexed to soluble receptor.

15 mutants resistant to preincubation with the soluble receptor.

16 y cytokines, chemokines, growth factors, and soluble receptors.

17 its normal receptors by administering decoy-soluble receptors.

18 trains tested were unable to target purified soluble receptors.

19 or antagonist and by binding to nonsignaling soluble receptors.

20 utative inhibitory, four activating and five soluble receptors.

21 oteome array bearing 62 cytokines/chemokines/soluble receptors.

22 lar endothelial growth factor (VEGF) and its soluble receptor-1 (sVEGFR-1, also known as sFlt-1) are

23 increased vascular endothelial growth factor soluble receptor-1 were also observed.

24 this study, we synthesized the stable, water-soluble receptor 1a as a structural mimic of the active

25 The mechanism underlying soluble receptor accumulation was found to be due to an

26 Ms) were cultured in media supplemented with soluble receptor activator of NF-kappaB ligand (RANKL) a

27 effect that was reversed by the addition of soluble receptor activator of nuclear factor kappa B lig

28 id (GCF) levels of interleukin (IL)-6, IL-8, soluble receptor activator of nuclear factor-kappa B lig

29 to compare the local and systemic levels of soluble receptor activator of nuclear factor-kappaB liga

30 l crevicular fluid (GCF) and serum levels of soluble receptor activator of nuclear factor-kappaB liga

31 CF samples of healthy teeth (P = 0.003), and soluble receptor activator of nuclear factor-kappaB liga

32 spin resonance spectroscopy of spin-labeled soluble receptors active in cells verify that the crysta

33 ssay and antiangiogenic efficacy of EphA2/Fc soluble receptors against VEGF/basic fibroblast growth f

34 Although soluble receptor agonist alone could not induce death, c

35 membrane-presented CD40 ligand (mCD40L), as soluble receptor agonists are but weakly pro-apoptotic.

36 orylation of p125FAK and can be modulated by soluble receptor agonists such as thrombin or via altere

37 ds that inhibit binding of human IL-5 to the soluble receptor alpha chain with IC50 of 8 microM and 1

38 A novel strategy with the use of soluble receptor analog(s) may be feasible in the preven

39 Recombinant mature human HB-EGF acts as a soluble receptor analog, binding radioiodinated DT and p

40 Competition experiments using heparin, a soluble receptor analog, demonstrated dose-dependent inh

41 A different series of soluble receptor analogs, named vasopressin receptor 1 e

42 overcome the inhibitory effect of heparin, a soluble receptor analogue, on gonococcal invasion of Cha

43 IL-33 and its soluble receptor and cell-associated receptor (ST2L) are

44 glycan-depleted trimers could still bind to soluble receptor and coreceptor analogs, suggesting a bl

45 rsible by IL-10 soluble receptor or TGF-beta soluble receptor and high concentration of anti-CTLA-4.

46 t with CEACAM1 was made adherent to both the soluble receptors and CEACAM1-transfected Chinese hamste

47 ecrosis factor-alpha) and IL (interleukin)-2 soluble receptors and NT-proBNP (N-Terminal Pro-B-Type N

48 mor necrosis factor-alpha by the addition of soluble receptors and receptor antagonists or following

49 ion between levels of TNF-alpha and of its 2 soluble receptors and the course of pregnancy and/or mal

50 as observed between the animals treated with soluble receptors and the untreated group with respect t

51 Biological therapies including antibodies, soluble receptors, and cytokines are being tested increa

52 Th2-type ILs, such as monoclonal antibodies, soluble receptors, and receptor antagonists, are a ratio

53 receptors, receptor-associated proteins, and soluble receptor antagonists.

54 The direct effects of the soluble receptors appear to be mediated through interact

55 Results revealed that levels of both soluble receptors are increased in systemic mastocytosis

56 After incubation with soluble receptor at 37 degrees C and pH 6.5, virions bec

57 s in hydrophobicity upon incubation with the soluble receptor at 37 degrees C, these findings indicat

58 is neutralized following incubation with the soluble receptor at 37 degrees C.

59 creased efficiency of envelope triggering by soluble receptor at low temperatures, as measured by pro

60 nding conformation at 37 degrees C either by soluble receptor at neutral pH or by alkaline pH alone,

61 o a conformational change at 37 degrees C by soluble receptor at neutral pH or by pH 8 alone.

62 Binding the soluble receptor at neutral pH resulted in virions capab

63 njection of a TNFalpha inhibitor, a TNFalpha soluble receptor, attenuated sleep deprivation-enhanced

64 enome, we identified a gene encoding a novel soluble receptor belonging to the class II cytokine rece

65 Conditions were established to express the soluble receptor binding domain (heavy-chain receptor [H

66 an be rendered infectious by the addition of soluble receptor-binding domain (RBD) proteins in the cu

67 interacts with the viral glycoprotein, and a soluble receptor-binding domain (SUA) binds sTva with pi

68 neutralizing antibodies or dominant-negative soluble receptor, blocks the growth of primary and metas

69 Both OSM and IL-6 (in the presence of its soluble receptor), but not IL-1 nor leukemia inhibitory

70 --ligand interactions requires expression of soluble receptor, but the production of functional solub

71 tion of the clearance of constitutively shed soluble receptor by receptor-specific mAb.

72 d in vitro, inhibition of binding of IL-6 to soluble receptor by the extract was not detected, but bi

73 age of cell-surface receptors, generation of soluble receptors by alternative gene splicing, transcri

74 The results of this study indicate that a soluble receptor can effectively block infection of at l

75 TNF-alpha, using a systemically administered soluble receptor, can enhance endothelial recovery and r

76 iciency virus type 1 (HIV-1) inactivation by soluble receptor CD4-IgG hybrid dimers (CD4-IgG) was exa

77 tor through the systemic administration of a soluble receptor chimeric protein (Flt-(1-3)-IgG) to 24-

78 ole for the immunophilin-like component of a soluble receptor complex and provides new insight into t

79 based on the human growth hormone (hGH).hGH soluble receptor complex structure suggests that the int

80 CD14 and MD-2 exist as soluble receptor components and are thought to bind to b

81 rties of individual BP domains, we generated soluble receptor consisting of individual BPs, as well a

82 SDS-PAGE-separated bacterial proteins using soluble receptor constructs as well as by co-precipitati

83 A soluble receptor containing the extracellular domain of

84 tected from LIGHT-mediated apoptosis by both soluble receptor, DcR3, and cIAP-2.

85 Thus, the soluble receptor designated IL-22BP inhibits IL-22 activ

86 Moreover, this soluble receptor, designated IL-22-binding protein (BP),

87 or, associated with the adaptor DAP12, and a soluble receptor detected at times of infection.

88 ngue hemorrhagic fever (DHF) by cytokine and soluble receptor detection in blood.

89 netics of the increased interferonemia, this soluble receptor does not potentiate its ligand signalin

90 ms, the proteolytic cleavage and shedding of soluble receptor ectodomains and the release of full-len

91 Soluble receptor efficiently mediated infection of cells

92 eptors on cytokine activity and we find that soluble receptors exhibit preferential cytokine blockade

93 stabilizing the high-affinity binding site; soluble receptors expressed after simple truncation at t

94 ncreased plasma proinflammatory cytokine and soluble receptor expression.

95 treated with tumor necrosis factor (TNF) p75 soluble receptor Fc conjugate (p75-Fc) remains unexplain

96 we developed a cell-free assay system using soluble receptor-Fc fusion proteins.

97 The resulting soluble receptor folded correctly and was no longer an i

98 1]), lactate dehydrogenase (5.7 [1.7-19.1]), soluble receptor for advanced glycation end products (3.

99 cally for the emphysema subpopulation is the soluble receptor for advanced glycation end products (sR

100 Circulating levels of soluble receptor for advanced glycation end products (sR

101 til now, no data exist regarding the role of soluble receptor for advanced glycation end products and

102 end products expression and decreased plasma soluble receptor for advanced glycation end products lev

103 vanced glycation end products expression and soluble receptor for advanced glycation end products lev

104 survivors had significantly decreased plasma soluble receptor for advanced glycation end products lev

105 ptor for advanced glycation end products and soluble receptor for advanced glycation end products may

106 cts expression might be deleterious, whereas soluble receptor for advanced glycation end products mig

107 he matrix metalloproteinase cleavage product soluble receptor for advanced glycation end products wer

108 roducts>103.6 mean fluorescence intensity or soluble receptor for advanced glycation end products<76.

109 area under the curve, 0.943+/-0.05; p<.001; soluble receptor for advanced glycation end products: ar

110 the relationship between early postoperative soluble receptor for advanced glycation end-product (sRA

111 e biomarkers surfactant protein D (SP-D) and soluble receptor for advanced glycation endproduct (sRAG

112 EVLWi, plasma concentrations of epithelial (soluble receptor for advanced glycation endproducts [sRA

113 n by co-incubation of AGE-treated cells with soluble receptor for AGE (sRAGE).

114 chymal stem cells (hBD-MSCs) with or without soluble receptor for AGEs (sRAGE).

115 Soluble receptor for ASLV-A induces a lipophilic charact

116 LPS signaling complex and can function as a soluble receptor for cells that do not otherwise express

117 serum-free leptin level by overexpressing a soluble receptor for leptin increased bone mass.

118 The histidine-binding protein, HisJ, is the soluble receptor for the periplasmic histidine permease

119 stantly related bacteria, where it acts as a soluble receptor for the ubiquitous signaling molecule c

120 ls of proinflammatory cytokines IL-6 and the soluble receptor for tumor necrosis factor-alpha (sTNFal

121 o markers of inflammatory activity, namely a soluble receptor for tumor necrosis factor-alpha (sTNFal

122 HSV) vector-mediated transfer of the cleaved soluble receptor for tumor necrosis factor-alpha (TNF-al

123 Soluble receptors for neuregulins blocked the effects of

124 ukin 6, high-sensitivity C-reactive protein, soluble receptors for tumor necrosis factor alpha 1 and

125 e clinical success of biologics (antibodies, soluble receptors) for treating TNF-based autoimmune con

126 The soluble receptor form of ST2 is secreted and detectable

127 The soluble receptor formed a 1/1 complex with IL-5 in solut

128 in the inner membrane, or they can comprise soluble receptors, forming arrays in the cytoplasm.

129 ptor short form, and 3) 293 cells expressing soluble receptor forms.

130 Two soluble receptor fragments comprising residues 143-210 o

131 ontaining overexpressed, intact receptor and soluble receptor fragments reconstituted into kinase-act

132 ture and function is derived from studies of soluble receptor fragments.

133 retion and neutrophil migration, whereas the soluble receptor functions as a counterregulatory molecu

134 el for the transport mechanism, in which the soluble receptor functions independently of the commonly

135 eceptor systems is limited because monomeric soluble receptors generally exhibit low affinity or func

136 The soluble receptor glycoproteins containing the N-terminal

137 HisQM to relay the inducing signal from the soluble receptor, HisJ, and that HisQM regulates the ATP

138 Neither the soluble receptor, HisJ, nor the transport substrate, his

139 Cytokines can be blocked by the use of soluble receptors; however, the use of this approach for

140 Treatment with a TNF-alpha-soluble receptor (human TNFR:Fc) significantly reduced e

141 l), IL-1 receptor antagonist (65 ng/ml), TNF soluble receptor I (3 ng/ml), and TNF soluble receptor I

142 Intrathecal TNF soluble receptor I (functionally blocking TNFalpha bioac

143 Here we have used soluble receptor-Ig forms of LT beta R and TNF-R55 and m

144 ), TNF soluble receptor I (3 ng/ml), and TNF soluble receptor II (14 ng/ml) accurately predicted mort

145 re performed using recombinant IL-33 and its soluble receptor IL-1RL1-a.

146 L-6 trans-signaling mediated by IL-6 and its soluble receptor IL-6R (sIL-6R); by an antibody to the I

147 (p = 0.001), TNF-alpha (p = 0.032) and their soluble receptors IL-6sr (p = 0.002), TNF-alpha sr1 (p =

148 d a significant association of interleukin 6 soluble receptor (IL-6 SR) with European ancestry on chr

149 s controlled by IL-6 in combination with its soluble receptor (IL-6 trans-signaling).

150 ane, soluble glycoprotein 130 (sGP130), IL-6 soluble receptor (IL-6sr), and C-reactive protein (CRP).

151 ase mRNA levels, but in the presence of IL-6-soluble receptor (IL-6sR), IL-6 caused a marked increase

152 increased by complexing this cytokine to its soluble receptor, IL-15R alpha.

153 P-1, and eotaxin) and anti-inflammatory (TNF soluble receptors, IL-10, IL-1 receptor antagonist) cyto

154 pretreatment plasma levels of interleukin-6 soluble receptor (IL6SR) and transforming growth factor

155 of mutant TNFRSF1A on the cell surface or as soluble receptor in plasma.

156 -1,3-glucan recognition protein (betaGRP), a soluble receptor in the hemolymph, binds to the surfaces

157 e receptor, but the production of functional soluble receptors in E. coli has generally proved diffic

158 s and circulating levels of TNF-alpha or its soluble receptors in the CHF patients.

159 sure to antigen would increase production of soluble receptors in the serum and BAL fluid (BALF) of b

160 wledge, this is the first demonstration that soluble receptors induce such behavioral disturbances.

161 no evidence that sIL-2Rs (or any peripheral soluble receptor) induce such behavioral changes, or tha

162 response to tumor cells, suggesting that the soluble receptor inhibited blood vessel recruitment by t

163 A recombinant soluble receptor inhibited T cell proliferation and IL-2

164 Administration of EphA2/Fc soluble receptors inhibited, in a dose-dependent manner,

165 d metalloproteinase enzymes that degrade the soluble receptor, inhibiting its VEGF-blocking activity.

166 evels were suppressed by the addition of BMP-soluble receptor inhibition of BMP ligand binding to its

167 f cytokine receptors allows the diffusion of soluble receptors into the extracellular space; these th

168 r data suggest that Vpr bypasses many of the soluble receptors involved in import of cellular cargoes

169 we demonstrate that the homodimeric IL-20R2 soluble receptor is a potent blocker for IL-24 and can b

170 Furthermore, we show that the effect of the soluble receptor is attenuated but not eliminated in Mst

171 ssed in human tissues while the Re form, the soluble receptor, is not expressed.

172 he KGFR were studied using surface-bound and soluble receptor isoforms expressed in wild type and mut

173 ive agents in vivo, and suggest that related soluble receptor isoforms expressed in wild-type mouse e

174 either plasma interleukin-6 or interleukin-6 soluble receptor levels.

175 ese results provide parameters for assessing soluble receptor-ligand interactions generally.

176 e FVIII endocytosis, competition assays with soluble receptor ligands, binding studies with recombina

177 sed competitive inhibition therapy, in which soluble receptors, ligands, and their analogs are employ

178 Blockade of LIGHT by its soluble receptors, lymphotoxin beta receptor-Ig or HVEM-

179 surfaces and the HSPG-independent binding to soluble receptor may be due to other molecule(s) present

180 apoptosis-inducing activity of CD30L by its soluble receptor may explain how CD30+ tumors escape imm

181 easures of disease severity, indicating that soluble receptors may reflect disease status.

182 Systemic, soluble receptor-mediated VEGF inhibition indicates an e

183 arlier and other studies have shown that the soluble receptors modulate the levels as well as activit

184 In vivo blockade of TNF-alpha using a soluble receptor molecule results in accelerated reendot

185 Consistent with the idea that soluble receptor molecules provide a trigger for HSV ent

186 r discrimination between surface-exposed and soluble receptor molecules.

187 The limiting signal is a soluble receptor, not a cytokine.

188 e, we show that inhibition of Notch, using a soluble receptor Notch1 decoy, unexpectedly caused a rem

189 Administration of anti-TNF or soluble receptor of advanced glycation end products atte

190 Osteoprotegerin (OPG), a soluble receptor of the cytokine TNF-related apoptosis-i

191 oy receptor 3 (TR6/DcR3) is an antiapoptosis soluble receptor of the TNF family produced by tumor cel

192 The water-soluble receptor of this permease, HisJ, binds L-histidi

193 LILRA3 is a soluble receptor of unknown functions but is predicted t

194 As soluble receptors of histamine, HBPs offer a new strateg

195 ough the nuclear pore complex is mediated by soluble receptors of the importin/exportin or karyopheri

196 We tested the effects of IL-6 and its soluble receptor on collagenase 3 expression in osteobla

197 e effects of local injection of IL-1 and TNF soluble receptors on a periodontal wound-healing model i

198 Thus, we evaluated the effect of the soluble receptors on cytokine activity and we find that

199 tumor necrosis factor high-molecular-weight soluble receptor (one trial, n=141) was not significantl

200 rast, blockade of LIGHT by administration of soluble receptor or antibody led to decreased cell-media

201 bserved, as assayed by direct binding of the soluble receptor or by functional assays using CD94/NKG2

202 ities were evaluated by binding assays using soluble receptor or intact receptor on cells as well as

203 uppression was partially reversible by IL-10 soluble receptor or TGF-beta soluble receptor and high c

204 es have reported that blocking TGF-beta with soluble receptors or siRNA can prevent the progression o

205 -01) was reversed by coadministration of TNF soluble receptors or the selective PKC inhibitor bisindo

206 dministration of tumor necrosis factor (TNF) soluble receptors, or ectopic expression of CrmA or domi

207 The secreted, soluble receptor osteoprotegerin (OPG) interrupts this a

208 taining various combinations of IL-6 and its soluble receptor over the concentration range 0 to 1,000

209 elated positively with tumor necrosis factor soluble receptors p55 and p75.

210 Indeed, soluble receptor-pretreated HCV fused with the cell plas

211 In this regard, the soluble receptor prevented IL-5-induced tyrosine phospho

212 1) similar constitutive TNF-alpha, IL-6, and soluble receptor production by control subjects and CBD

213 f the system by measurements of antibody and soluble receptor protein binding to BIOTRX fusions immob

214 The soluble receptor protein described here represents a val

215 Soluble receptor proteins derived from the macrophage-mo

216 ptosis occurs via the LIGHT pathway and that soluble receptors provide protection.

217 Soluble receptor purified from mammalian cells is able t

218 The transcript encoding the soluble receptor (Re) includes 14 coding exons and an al

219 addition, OX-2 transfectants do not bind the soluble receptor reagents of the B7/CD28 pathway (CD28-I

220 levels of cytokines and their corresponding soluble receptor/receptor antagonists significantly incr

221 -6 [IL-6] and interleukin-2 [IL-2] and their soluble receptor/receptor antagonists).

222 We isolated and sequenced 24 soluble receptor-resistant (srr) mutants and characteriz

223 Pex7p is the soluble receptor responsible for importing into peroxiso

224 er, addition of IL-6 in combination with its soluble receptor resulted in a statistically significant

225 g assay, in which administration of EphA2/Fc soluble receptors resulted in 81% inhibition of neovascu

226 Of interest, this soluble receptor retained the ability to signal from the

227 Both soluble receptor sequestration of VEGF and small molecul

228 Using recombinant chimeric soluble receptors, siglec-transfected cell lines and mac

229 Furthermore, coadministration of TNF soluble receptor significantly attenuated PMA/FP-induced

230 The IL-6 soluble receptor (sIL-6R) increases IL-6 activity, and I

231 (TNFalpha), and interleukin-6 (IL-6) and its soluble receptor (sIL-6R) on immature bovine and adult h

232 ncentrations of interleukin-6 (IL-6) and its soluble receptor (sIL-6R), high-sensitivity C-reactive p

233 s, only OSM and IL-6, in the presence of its soluble receptor (sIL-6R), were able to act synergistica

234 pathway stimulated by IL6 complexed with its soluble receptor (sIL6R) contributes to emergency granul

235 In addition, we illustrate how a soluble receptor, sMUC18, for the therapeutic mAb ABX-MA

236 binding of subneutralizing concentrations of soluble receptor, soluble CD4 (sCD4), or monoclonal anti

237 Concentrations of VEGF and its soluble receptor, soluble fms-like tyrosine kinase 1 (sF

238 F-alpha) and lnterleukin-6 (IL-6), and their soluble receptors, soluble TNF receptor I (sTNF RI), sTN

239 IL-4 and IL-13 are each bound by soluble receptors (sRs) that block their activity.

240 d receptor (ST2L) activated by IL33 and as a soluble receptor (sST2) with anti-inflammatory propertie

241 mor necrosis factor alpha (TNFalpha) and its soluble receptors (sTNFalpha) to assess the relationship

242 udinal study indicate that TNF-alpha (or its soluble receptor, sTNFp55) is increased in the periphera

243 aled that a dimeric form of the human 80 kDa soluble receptor (sTNFR:Fc) for tumor necrosis factor (T

244 The importance of TNF-alpha and its soluble receptors (sTNFR1 and sTNFR2) in the development

245 Expression of the p55 TNF soluble receptor (sTNFRs) by HSV-mediated gene transfer

246 t experiments, we demonstrated that EphA2/Fc soluble receptors strongly (by approximately 50% versus

247 lpha; CD25; Tac) is the prototypic model for soluble receptor studies.

248 rodimeric cytokine composed of the IL-12p40 "soluble receptor" subunit and a novel cytokine-like subu

249 The IL-27 cytokine and soluble receptor subunits p28 and EBI3 can be secreted i

250 These studies using highly specific soluble receptors suggest that additivity between VEGFR

251 but not by saturating concentrations of TNF-soluble receptor, suggesting that intracellular TNFalpha

252 ation of Lys(139) and His(143) to alanine in soluble receptor (suPAR) reduced the affinity for scuPA

253 heW complex in the absence and presence of a soluble receptor that inhibits kinase activity (Tm14).

254 Researchers have identified a soluble receptor that prevents blood vessels forming in

255 hat systemic inflammation or lower levels of soluble receptors that bind inflammatory cytokines incre

256 This method was used to construct soluble receptors that bind trinitrotoluene, l-lactate o

257 Tumor cells can induce certain cytokines and soluble receptors that have a suppressive effect on the

258 asmic transport of macromolecules, utilizing soluble receptors that identify and present cargo to the

259 cleavage of TNF receptor 1 (TNFR1) generates soluble receptors that regulate TNF bioactivity.

260 (HisQMP2) containing four subunits, and of a soluble receptor, the histidine-binding protein (HisJ).

261 The liganded soluble receptor, the histidine-binding protein HisJ, in

262 on induction of the activity by the liganded soluble receptor, the periplasmic histidine-binding prot

263 By forming a complex with its soluble receptor, the proinflammatory cytokine interleuk

264 nd complex containing four subunits and of a soluble receptor, the substrate-binding protein (HisJ),

265 actors including angiopoietin-2 (Ang-2), its soluble receptor Tie-2 (sTie-2), and hepatocyte growth f

266 thesis that plasma angiopoietin (Ang-1), its soluble receptor tie-2, and Ang-2 levels would be abnorm

267 n crystal structure of a Thermotoga maritima soluble receptor (Tm14) reveals distortions in its dimer

268 was accompanied by a significant increase in soluble receptors, TNF-SRI (159 pg/ml vs 206 pg/ml) and

269 its acute effects are limited by binding to soluble receptors (TNFR), suggesting that TNFR genes cou

270 TNF soluble receptor (TNFsr) has been shown to neutralize th

271 Binding of soluble receptor to API induces API to bind to liposomes

272 Binding of soluble receptor to H is sufficient to initiate refoldin

273 tivity was inhibited by local application of soluble receptors to IL-1 and TNF by injection into inte

274 The results indicate that injection of soluble receptors to IL-1 and TNF inhibited by approxima

275 Function-blocking soluble receptors to IL-1 and TNF were applied by local

276 ed by a non-genetic approach using exogenous soluble receptors to inhibit all activin signalling in t

277 EGF or PDGF alone, by adenovirally generated soluble receptors, to the effects of inhibiting both tog

278 lysates from all three sources although the soluble receptor, TR6, was scarce in placentas and all r

279 Using either soluble receptor traps consisting of the extracellular l

280 y C-reactive protein, oxidized LDL antibody, soluble receptor tumor necrosis factor, tumor necrosis f

281 (two trials, n=151) and low-molecular-weight soluble receptor (two trials, n=1,786) had similar benef

282 or necrosis factor-alpha (TNF-alpha) and its soluble receptor type II (sTNF-RII) is well documented,

283 CHF, circulating levels of TNF-alpha and the soluble receptors type I and type II were measured by EL

284 ase-type plasminogen activator (uPA) and its soluble receptor (uPAR) would predict cancer of the pros

285 ated with neutralizing TGFbeta antibodies or soluble receptor variants.

286 When the soluble receptor was administered at the time of injury,

287 brane KGF receptor cDNA, suggesting that the soluble receptor was generated by mRNA splicing and prob

288 als receiving control IgG (P < 0.0002); when soluble receptor was given after injury induction, colla

289 bsence of RAP co-expression, over 50% of the soluble receptor was secreted in the presence of RAP co-

290 Upon aspartate binding, this soluble receptor was stabilized to a similar extent as t

291 The soluble receptor was used in a scintillation proximity a

292 This "soluble receptor" was infused at the time of injury; in

293 ulate the capacity of IL-6 to signal via its soluble receptor, we report that local control of IL-6 t

294 necrosis factor alpha (TNF-alpha), and their soluble receptors were determined for 68 patients.

295 n markers, inflammatory mediators, and their soluble receptors were determined.

296 Both ligands and soluble receptors were found to be monomeric in solution

297 Baseline concentrations of TNF and its soluble receptors were significantly higher in inflixima

298 When both soluble receptors were used together, there was a greate

299 with high plasma levels of TNFalpha and its soluble receptors, which in turn may lead to a hyperinfl

300 ound that monkey kidney COS1 cells express a soluble receptor with molecular mass of approximately 55